Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 375

1.

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.

Clin Cancer Res. 2007 Mar 1;13(5):1540-51.

2.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.

Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.

Mol Cancer Ther. 2009 Jun;8(6):1536-46. doi: 10.1158/1535-7163.MCT-08-0978. Epub 2009 Jun 9.

4.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

5.

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.

Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K.

Br J Cancer. 2008 Feb 26;98(4):749-55. doi: 10.1038/sj.bjc.6604222. Epub 2008 Feb 5.

6.

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.

Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.

Clin Cancer Res. 2010 Oct 15;16(20):4990-5001. doi: 10.1158/1078-0432.CCR-10-0923. Epub 2010 Sep 1.

7.

[Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].

Wang M, Zhang L, Zhao X, Liu J, Chen Y, Wang C.

Zhonghua Zhong Liu Za Zhi. 2014 Sep;36(9):651-6. Chinese.

PMID:
25564053
8.

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.

Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G.

Anticancer Drugs. 2004 Jun;15(5):503-12.

PMID:
15166626
9.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

10.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
11.

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.

Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A.

Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91.

12.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.

Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, Hicklin DJ, Hadari YR.

Mol Cancer Ther. 2007 Oct;6(10):2642-51. Epub 2007 Oct 3.

13.
14.

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M.

Cancer Sci. 2009 Aug;100(8):1526-31. doi: 10.1111/j.1349-7006.2009.01197.x. Epub 2009 May 13.

15.
16.

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Bao C, Bassi R, Prewett M, Tonra JR.

Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92.

PMID:
22399498
17.

Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.

Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O.

Anticancer Res. 2013 Sep;33(9):3615-21.

PMID:
24023287
18.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

19.

ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC.

Lung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27.

PMID:
27040853
20.

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.

Han C, Huang Z, Zheng C, Wan L, Zhang L, Peng S, Ding K, Ji H, Tian J, Zhang Y.

J Med Chem. 2013 Jun 13;56(11):4738-48. doi: 10.1021/jm400463q. Epub 2013 May 24.

PMID:
23668441

Supplemental Content

Support Center